Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...
Zacks Investment Research on MSN
Denali Therapeutics unveils portfolio goals for 2026, stock up
Denali Therapeutics Inc. DNLI recently outlined its roadmap for 2026 across its portfolio of investigational therapies for ...
Denali Therapeutics (DNLI) drew fresh interest after publishing Phase 1/2 trial results for its Hunter syndrome therapy, ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Denali Therapeutics (DNLI) announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for ...
The Gulf of Mexico has been renamed to the Gulf of America, the Interior Department announced Friday, while the name of North America's highest peak, Alaska's Denali, has been changed back to Mount ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback